{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:15:59Z","timestamp":1794384959490,"version":"4.9.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Despite major therapeutic advances, many patients with inflammatory bowel disease (IBD) continue to experience inadequate treatment response, progressive disease, and irreversible complications requiring surgery. Current management is constrained by a biological efficacy ceiling and lack of agents directly targeting key drivers of fibrosis and barrier dysfunction. This systematic review synthesizes current knowledge on tumor necrosis factor-like cytokine 1A (TL1A) and death-domain receptor 3 (DR3) signaling pathways, critically evaluates the therapeutic potential of TL1A-targeted interventions, and explores future directions for precision medicine applications in IBD care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive systematic search of PubMed, EMBASE, Cochrane library, Web of Science, and ClinicalTrials.gov was conducted according to PRISMA guidelines. Three independent reviewers screened preclinical and clinical studies using Rayyan software. Study selection, data extraction, and quality assessment were performed in duplicate. Eligible studies underwent narrative thematic synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 250 studies identified, 63 met inclusion criteria. Preclinical data consistently demonstrate TL1A-DR3 signaling drives inflammation, fibrosis, and barrier dysfunction. Phase 2 clinical trials showed anti-TL1A monoclonal antibodies (Tulisokibart, Afimkibart, Duvakitug) achieved clinical remission\/response rates between 26% and 66% in patients with moderate-to-severe IBD at 12-14\u2009weeks, with favorable safety profiles. Emerging themes include extended dosing intervals, therapeutic benefit in treatment-refractory populations, potential anti-fibrotic effects, and opportunities for biomarker-guided patient stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TL1A inhibitors represent a promising novel therapeutic class with dual anti-inflammatory and anti-fibrotic properties, addressing critical unmet clinical needs in IBD. These agents hold the potential to become cornerstone therapies in the evolving landscape of precision medicine for IBD care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag039","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:37:10Z","timestamp":1775907430000},"source":"Crossref","is-referenced-by-count":4,"title":["TL1A as a therapeutic renaissance in inflammatory bowel disease: a systematic review from molecular mechanisms to clinical translation"],"prefix":"10.1093","volume":"20","author":[{"given":"Raymond Fueng-Hin","family":"Liang","sequence":"first","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6043-3231","authenticated-orcid":false,"given":"Cecilia Lina","family":"Pugliano","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8237-5508","authenticated-orcid":false,"given":"Robert","family":"Hughes","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehali","family":"Majumder","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lo Bello","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-9550","authenticated-orcid":false,"given":"Marietta","family":"Iacucci","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland, College of Medicine and Health, University College Cork , Cork,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026052115483021900_jjag039-B1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026052115483021900_jjag039-B2","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1016\/j.cgh.2020.10.008","article-title":"Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study","volume":"20","author":"Khoudari","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026052115483021900_jjag039-B3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"key":"2026052115483021900_jjag039-B4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1074-7613(02)00283-2","article-title":"TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator","volume":"16","author":"Migone","year":"2002","journal-title":"Immunity"},{"key":"2026052115483021900_jjag039-B5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.medj.2024.03.010","article-title":"TL1A inhibition for inflammatory bowel disease treatment: from inflammation to fibrosis","volume":"5","author":"Solitano","year":"2024","journal-title":"Med."},{"key":"2026052115483021900_jjag039-B6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-021-00543-0","article-title":"Revisiting fibrosis in inflammatory bowel disease: the gut thickens","volume":"19","author":"D\u2019Alessio","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2026052115483021900_jjag039-B7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026052115483021900_jjag039-B8","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026052115483021900_jjag039-B9","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026052115483021900_jjag039-B10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"2026052115483021900_jjag039-B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods."},{"key":"2026052115483021900_jjag039-B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1556\/EuJMI.3.2013.1.2","article-title":"Sustained TL1A (TNFSF15) expression on both lymphoid and myeloid cells leads to mild spontaneous intestinal inflammation and fibrosis","volume":"3","author":"Zheng","year":"2013","journal-title":"Eur J Microbiol Immunol (Bp)."},{"key":"2026052115483021900_jjag039-B13","doi-asserted-by":"crossref","first-page":"e16090","DOI":"10.1371\/journal.pone.0016090","article-title":"Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis","volume":"6","author":"Shih","year":"2011","journal-title":"PLoS One."},{"key":"2026052115483021900_jjag039-B14","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1073\/pnas.0510903103","article-title":"Role of TL1A and its receptor DR3 in two models of chronic murine ileitis","volume":"103","author":"Bamias","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026052115483021900_jjag039-B15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.gastro.2008.04.037","article-title":"TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-Helper 1 and T-Helper 17 activation","volume":"135","author":"Takedatsu","year":"2008","journal-title":"Gastroenterology"},{"key":"2026052115483021900_jjag039-B16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/mi.2010.67","article-title":"The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation","volume":"4","author":"Meylan","year":"2011","journal-title":"Mucosal Immunol."},{"key":"2026052115483021900_jjag039-B17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajpath.2011.10.026","article-title":"Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis","volume":"180","author":"Barrett","year":"2012","journal-title":"Am J Pathol."},{"key":"2026052115483021900_jjag039-B18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ibd.21124","article-title":"TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn\u2019s disease","volume":"16","author":"Kamada","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2026052115483021900_jjag039-B19","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.4049\/jimmunol.171.9.4868","article-title":"Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease","volume":"171","author":"Bamias","year":"2003","journal-title":"J Immunol."},{"key":"2026052115483021900_jjag039-B20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2004.02.007","article-title":"Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-\u03b3, in mucosal inflammation","volume":"112","author":"Prehn","year":"2004","journal-title":"Clin Immunol"},{"key":"2026052115483021900_jjag039-B21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clim.2010.07.001","article-title":"High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis","volume":"137","author":"Bamias","year":"2010","journal-title":"Clin Immunol."},{"key":"2026052115483021900_jjag039-B22","doi-asserted-by":"crossref","first-page":"e4719","DOI":"10.1371\/journal.pone.0004719","article-title":"IBD-associated TL1A Gene (TNFSF15) haplotypes determine increased expression of TL1A protein","volume":"4","author":"Michelsen","year":"2009","journal-title":"PLoS One."},{"key":"2026052115483021900_jjag039-B23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/MIB.0000000000000653","article-title":"Differential levels of Tl1a affect the expansion and function of regulatory T cells in modulating murine colitis","volume":"22","author":"Sidhu-Varma","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2026052115483021900_jjag039-B24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.trsl.2016.08.007","article-title":"Crohn\u2019s disease-associated mucosal factors regulate the expression of TNF-like cytokine 1A and its receptors in primary subepithelial intestinal myofibroblasts and intestinal epithelial cells","volume":"180","author":"Bamias","year":"2017","journal-title":"Transl Res."},{"key":"2026052115483021900_jjag039-B25","doi-asserted-by":"crossref","first-page":"5927064","DOI":"10.1155\/2021\/5927064","article-title":"Effect and mechanism of TL1A expression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis","volume":"2021","author":"Wenxiu","year":"2021","journal-title":"Mediators Inflamm."},{"key":"2026052115483021900_jjag039-B26","doi-asserted-by":"crossref","first-page":"18189","DOI":"10.1038\/s41598-020-75168-5","article-title":"Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo","volume":"10","author":"Jacob","year":"2020","journal-title":"Sci Rep."},{"key":"2026052115483021900_jjag039-B27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11596-024-2875-1","article-title":"TL1A promotes fibrogenesis in colonic fibroblasts via the TGF-\u03b21\/Smad3 signaling pathway","volume":"44","author":"Song","year":"2024","journal-title":"Curr Med Sci."},{"key":"2026052115483021900_jjag039-B28","doi-asserted-by":"crossref","first-page":"goae103","DOI":"10.1093\/gastro\/goae103","article-title":"TNFSF15 variant predicts disease progression in Chinese patients with Crohn\u2019s disease","volume":"12","author":"Zhang","year":"2024","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"2026052115483021900_jjag039-B29","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/eji.200839087","article-title":"Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells","volume":"39","author":"Shih","year":"2009","journal-title":"Eur J Immunol."},{"key":"2026052115483021900_jjag039-B30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/s41385-018-0055-y","article-title":"Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome","volume":"11","author":"Jacob","year":"2018","journal-title":"Mucosal Immunol."},{"key":"2026052115483021900_jjag039-B31","doi-asserted-by":"crossref","first-page":"S1274","DOI":"10.1016\/S0016-5085(24)03376-6","article-title":"Tu1188 intraepithelial bacteria repress DKK1 signaling to promote intestinal fibrosis in TL1A-transgenic mice","volume":"166","author":"Pai","year":"2024","journal-title":"Gastroenterology"},{"key":"2026052115483021900_jjag039-B32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.prp.2017.11.017","article-title":"TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice","volume":"214","author":"Li","year":"2018","journal-title":"Pathol Res Pract"},{"key":"2026052115483021900_jjag039-B33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/19420862.2018.1440164","article-title":"An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease","volume":"10","author":"Clarke","year":"2018","journal-title":"Mabs."},{"key":"2026052115483021900_jjag039-B34","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mi.2014.37","article-title":"Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis","volume":"7","author":"Shih","year":"2014","journal-title":"Mucosal Immunol."},{"key":"2026052115483021900_jjag039-B35","doi-asserted-by":"crossref","first-page":"i1656","DOI":"10.1093\/ecco-jcc\/jjad212.1041","article-title":"Development and characterization of SPY002, a novel extended half-life monoclonal antibody drug candidate targeting TL1A for the treatment of IBD","volume":"18","author":"Zhu","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"2026052115483021900_jjag039-B36","doi-asserted-by":"crossref","first-page":"i1258","DOI":"10.1093\/ecco-jcc\/jjae190.0814","article-title":"Development and characterization of LQ080, a novel extended half-life bispecific TL1A\/IL-23 p19 single domain antibody for the treatment of IBD","volume":"19","author":"Wan","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"2026052115483021900_jjag039-B37","doi-asserted-by":"crossref","first-page":"i1594","DOI":"10.1093\/ecco-jcc\/jjae190.1009","article-title":"AI-guided generation and development of HXN-1001, a highly potent and half-life extended anti-TL1A antibody","volume":"19","author":"Huang","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"2026052115483021900_jjag039-B38","doi-asserted-by":"crossref","first-page":"i2046","DOI":"10.1093\/ecco-jcc\/jjae190.1288","article-title":"Engineering and development of a novel bispecific antibody targeting IL-23 and TL1A","volume":"19","author":"Huang","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"2026052115483021900_jjag039-B39","doi-asserted-by":"crossref","DOI":"10.1093\/jimmun\/vkaf283.2321","article-title":"Discovery and development of SIM0709, a novel bi-specific antibody targeting TL1A and IL23p19 for the treatment of IBD and beyond 4676","volume":"214","author":"Zhao","year":"2025","journal-title":"J Immunol"},{"key":"2026052115483021900_jjag039-B40","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2025-SITC2025.0399","article-title":"Preclinical efficacy evaluation for TL1A antibody related drug on TNBS- induced acute colitis model in transgenic humanized mice","volume":"13","author":"Yan","year":"2025","journal-title":"J. Immunotherapoy Cancer"},{"key":"2026052115483021900_jjag039-B41","doi-asserted-by":"crossref","first-page":"i79","DOI":"10.1093\/ecco-jcc\/jjae190.0039B","article-title":"Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)","volume":"19","author":"Reinisch","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"2026052115483021900_jjag039-B42","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1093\/ecco-jcc\/jjae190.0039A","article-title":"Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn\u2019s disease: results from a phase 2b, randomised, double-blind, placebo-c","volume":"19","author":"Jairath","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026052115483021900_jjag039-B43","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med."},{"key":"2026052115483021900_jjag039-B44","doi-asserted-by":"crossref","first-page":"i1993","DOI":"10.1093\/ecco-jcc\/jjae190.1259","article-title":"Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: a post-hoc analysis from ARTEMIS-UC","volume":"19","author":"Peyrin-Biroulet","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"2026052115483021900_jjag039-B45","first-page":"A10","article-title":"Long-term efficacy and safety of tulisokibart in participants with ulcerative colitis: the open-label extension of the phase 2 ARTEMIS-UC study","volume":"74","author":"Hoque","year":"2025","journal-title":"Gut"},{"key":"2026052115483021900_jjag039-B46","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: a phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026052115483021900_jjag039-B47","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2026052115483021900_jjag039-B48","doi-asserted-by":"crossref","first-page":"i75","DOI":"10.1093\/ecco-jcc\/jjae190.0039","article-title":"Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis \u2013 results from TUSCANY-2","volume":"19","author":"Jairath","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026052115483021900_jjag039-B49","doi-asserted-by":"crossref","first-page":"i1802","DOI":"10.1093\/ecco-jcc\/jjad212.1128","article-title":"Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn\u2019s disease (RELIEVE UCCD)","volume":"18","author":"Reinisch","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026052115483021900_jjag039-B50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2468-1253(25)00071-8","article-title":"Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn\u2019s disease: a phase 2a induction trial","volume":"10","author":"Feagan","year":"2025","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2026052115483021900_jjag039-B51","doi-asserted-by":"crossref","first-page":"S-806","DOI":"10.1016\/S0016-5085(24)02336-9","article-title":"Early change in CDAI predicts improved quality of life after 12-week induction therapy with tulisokibart in patients with moderately to severely active Crohn\u2019s Disease: a post hoc analysis from Apollo-CD","volume":"166","author":"Siegel","year":"2024","journal-title":"Gastroenterology"},{"key":"2026052115483021900_jjag039-B52","doi-asserted-by":"crossref","first-page":"S-2082","DOI":"10.1016\/S0016-5085(25)05720-8","article-title":"Duvakitug induction treatment improves endoscopic and patient-reported clinical outcomes in patients with Crohn\u2019s Disease: an endoscopic subgroup analysis of data from the relieve-UCCD phase 2B study","volume":"169","author":"Jairath","year":"2025","journal-title":"Gastroenterology"},{"key":"2026052115483021900_jjag039-B53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ijms25052789","article-title":"Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease","volume":"25","author":"Puca","year":"2024","journal-title":"Int J Mol Sci."},{"key":"2026052115483021900_jjag039-B54","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mi.2012.124","article-title":"TL1A\/TNFSF15 directly induces proinflammatory cytokines, including TNF\u03b1, from CD3+CD161+ T cells to exacerbate gut inflammation","volume":"6","author":"Jin","year":"2013","journal-title":"Mucosal Immunol."},{"key":"2026052115483021900_jjag039-B55","doi-asserted-by":"crossref","first-page":"i1445","DOI":"10.1093\/ecco-jcc\/jjae190.0923","article-title":"Infection adverse events with tulisokibart over 50 weeks of treatment in the phase 2 Crohn\u2019s disease Apollo-CD trial","volume":"19","author":"Sabino","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026052115483021900_jjag039-B56","doi-asserted-by":"crossref","first-page":"258164","DOI":"10.1155\/2013\/258164","article-title":"The role of TL1A and DR3 in autoimmune and inflammatory diseases","volume":"2013","author":"Aiba","year":"2013","journal-title":"Mediators Inflamm."},{"key":"2026052115483021900_jjag039-B57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2025.02.018","article-title":"TL1A, a novel alarmin in airway, intestinal, and autoimmune disorders","volume":"155","author":"Varricchi","year":"2025","journal-title":"J Allergy Clin Immunol."},{"key":"2026052115483021900_jjag039-B58","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3389\/fimmu.2019.00583","article-title":"TL1A (TNFSF15) and DR3 (TNFRSF25): A co-stimulatory system of cytokines with diverse functions in gut mucosal immunity","volume":"10","author":"Valatas","year":"2019","journal-title":"Front Immunol."},{"key":"2026052115483021900_jjag039-B59","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.immuni.2018.10.014","article-title":"Microbiota-induced TNF-like ligand 1A drives Group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during Colitis","volume":"49","author":"Castellanos","year":"2018","journal-title":"Immunity"},{"key":"2026052115483021900_jjag039-B60"},{"key":"2026052115483021900_jjag039-B61"},{"key":"2026052115483021900_jjag039-B62"},{"key":"2026052115483021900_jjag039-B63"},{"key":"2026052115483021900_jjag039-B64"},{"key":"2026052115483021900_jjag039-B65"},{"key":"2026052115483021900_jjag039-B66"},{"key":"2026052115483021900_jjag039-B67"},{"key":"2026052115483021900_jjag039-B68"},{"key":"2026052115483021900_jjag039-B69"},{"key":"2026052115483021900_jjag039-B70"},{"key":"2026052115483021900_jjag039-B71"},{"key":"2026052115483021900_jjag039-B72"},{"key":"2026052115483021900_jjag039-B73"},{"key":"2026052115483021900_jjag039-B74"},{"key":"2026052115483021900_jjag039-B75","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/384372a0","article-title":"A death-domain-containing receptor that mediates apoptosis","volume":"384","author":"Kitson","year":"1996","journal-title":"Nature"},{"key":"2026052115483021900_jjag039-B76","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"key":"2026052115483021900_jjag039-B77","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.4049\/jimmunol.178.7.4033","article-title":"The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells","volume":"178","author":"Prehn","year":"2007","journal-title":"J Immunol."},{"key":"2026052115483021900_jjag039-B78","doi-asserted-by":"crossref","first-page":"e20231236","DOI":"10.1084\/jem.20231236","article-title":"TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation","volume":"221","author":"Schmitt","year":"2024","journal-title":"J Exp Med"},{"key":"2026052115483021900_jjag039-B79","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jmcb\/mjv012","article-title":"Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation","volume":"7","author":"Madouri","year":"2015","journal-title":"J Mol Cell Biol."},{"key":"2026052115483021900_jjag039-B80","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41420-025-02630-6","article-title":"IL-33-primed NLRP3 inflammasome in basophils drives IL-1\u03b2 production and initiates atopic dermatitis inflammation","volume":"11","author":"Gunji","year":"2025","journal-title":"Cell Death Discov."},{"key":"2026052115483021900_jjag039-B81","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/25387","article-title":"Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer","volume":"396","author":"Pitti","year":"1998","journal-title":"Nature"},{"key":"2026052115483021900_jjag039-B82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcmgh.2023.03.008","article-title":"DR3 regulates intestinal epithelial homeostasis and regeneration after intestinal barrier injury","volume":"16","author":"Shimodaira","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"2026052115483021900_jjag039-B83","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s10620-019-05580-z","article-title":"Effects and mechanism of constitutive TL1A expression on intestinal mucosal barrier in DSS-induced colitis","volume":"64","author":"Yang","year":"2019","journal-title":"Dig Dis Sci."},{"key":"2026052115483021900_jjag039-B84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00384-019-03479-9","article-title":"Meta-analysis of early bowel resection versus initial medical therapy in patient\u2019s with ileocolonic Crohn\u2019s disease","volume":"35","author":"Ryan","year":"2020","journal-title":"Int J Colorectal Dis."},{"key":"2026052115483021900_jjag039-B85","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1093\/ecco-jcc\/jjz203.575","article-title":"Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study","volume":"14","author":"Hassan-Zahraee","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026052115483021900_jjag039-B86","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s10067-017-3612-y","article-title":"Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis","volume":"36","author":"Xu","year":"2017","journal-title":"Clin Rheumatol."},{"key":"2026052115483021900_jjag039-B87","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13075-020-02198-9","article-title":"Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF","volume":"22","author":"Song","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026052115483021900_jjag039-B88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clim.2008.07.014","article-title":"Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis","volume":"129","author":"Bamias","year":"2008","journal-title":"Clin Immunol."},{"key":"2026052115483021900_jjag039-B89","doi-asserted-by":"crossref","first-page":"7325","DOI":"10.4049\/jimmunol.178.11.7325","article-title":"Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis","volume":"178","author":"Cassatella","year":"2007","journal-title":"J Immunol."},{"key":"2026052115483021900_jjag039-B90","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms24031813","article-title":"Increased serum levels of tumor necrosis factor-like Ligand 1A in atopic dermatitis","volume":"24","author":"Hisamoto","year":"2023","journal-title":"Int J Mol Sci."},{"key":"2026052115483021900_jjag039-B91","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apm.12385","article-title":"Secretion, blood levels and cutaneous expression of TL1A in psoriasis patients","volume":"123","author":"Pedersen","year":"2015","journal-title":"APMIS"},{"key":"2026052115483021900_jjag039-B92","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1600-0625.2011.01304.x","article-title":"Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions","volume":"20","author":"Bamias","year":"2011","journal-title":"Exp Dermatol."},{"key":"2026052115483021900_jjag039-B93","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00403-014-1497-z","article-title":"TNF-like ligand 1A is associated with the pathogenesis of psoriasis vulgaris and contributes to IL-17 production in PBMCs","volume":"306","author":"Li","year":"2014","journal-title":"Arch Dermatol Res."},{"key":"2026052115483021900_jjag039-B94","doi-asserted-by":"crossref","first-page":"8543720","DOI":"10.1155\/2022\/8543720","article-title":"Interleukin-22 ameliorates dextran sulfate sodium-induced colitis through the upregulation of lncRNA-UCL to accelerate Claudin-1 expression via sequestering miR-568 in mice","volume":"2022","author":"He","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"2026052115483021900_jjag039-B95","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jimmun\/vkaf002","article-title":"Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis","volume":"214","author":"Steele","year":"2025","journal-title":"J Immunol."},{"key":"2026052115483021900_jjag039-B96","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.4049\/jimmunol.2000665","article-title":"TL1A promotes lung tissue fibrosis and airway remodeling","volume":"205","author":"Herro","year":"2020","journal-title":"J Immunol."},{"key":"2026052115483021900_jjag039-B97"},{"key":"2026052115483021900_jjag039-B98","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nbt.2621","article-title":"Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies","volume":"31","author":"Spiess","year":"2013","journal-title":"Nat Biotechnol."},{"key":"2026052115483021900_jjag039-B99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fmolb.2017.00061","article-title":"Increased potency of a bi-specific TL1A-ADAM17 (TACE) inhibitor by cell surface targeting","volume":"4","author":"Weizman","year":"2017","journal-title":"Front Mol Biosci."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag039\/68361947\/jjag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/5\/jjag039\/68361947\/jjag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:48:49Z","timestamp":1779392929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag039\/8690115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag039","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"jjag039"}}